

13670 COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

STATEMENT BY
HENRY T. RICKETTS, MD
PROFESSOR OF MEDICINE EMERITUS,
UNIVERSITY OF CHICAGO,
950 EAST 59TH STREET,
CHICAGO, ILLINOIS 60637.
BEFORE THE SUBCOMMITTEE
OF THE SELECT COMMITTEE,
ON SENATE SMALL BUSINESS,
JANUARY 31, 1975

I have studied diabetes mellitus, cared for diabetic patients, and conducted researches in this specialty for 34 years. I have been president of the American Diabetes Association and co-founder and president of the Chicago Diabetes Association. I have served on the Study Section of Endocrinology and Metabolism, Grants Division, National Institute of Arthritis and Metabolic Diseases, and have served as a contributor and an associate editor of the journal, Diabetes.

My connection with the Committee of the Biometric Society was that of a consultant diabetologist, and I attended most of their meetings. I was struck by the thoroughness with which the members of the Committee made their investigation. I detected no bias for or against the UGDP study. The Committee listened to more who criticized the study than to those who were less opposed or favorable. The Committee did not hesitate to ask the Coordinating Center in Baltimore for raw data when a point was in doubt, and members made trips to the Center and to several participating clinics to check methods, procedures, and results. No uncertainty was too small to leave unresolved.